VLU has a value, but the pipeline is very valuable too.
The technology is based on a protein that can be modified and structured to aim at many market needs.
The market main advantage is the simplicity of the applications and clearly the low treatment cost in general (for VLU now, but DFU, Ocular and hope soon in the preventive treatment of any type of dermatogical disease).
Wish the best and success.
Some random thoughts on valuation..., page-6
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
